Longevity Lab Report

News

Hims & Hers Will Sell Three Unapproved Peptides This Month, With BPC-157 and TB-500 to Follow

What the company actually announced, what the federal draft does and does not do, and the grades on the two peptides named as next.

Saved articles

Ask ChatGPT about this article ↗

Copy the prompt, then paste it into ChatGPT to explore the findings and sources.

Open ChatGPT ↗

What happened

Hims & Hers will sell glutathione, sermorelin, and NAD+ this month, none of them FDA approved, and plans BPC-157 and TB-500 later under a federal enforcement-discretion draft that approves nothing. Our library grades BPC-157 and TB-500 D on evidence. The public comment window on the draft closes Friday.

Hims & Hers, the national telehealth company, said on Monday, November 9 that it will begin selling three wellness products this month: glutathione, sermorelin, and NAD+. None of the three is FDA approved. The company said it will later add the two peptides its customers ask about most, BPC-157 and TB-500, and will manufacture those two in the United States. Reuters reported the announcement the day it was made, and its copy carries the sentence the rest of the coverage tends to drop: the federal policy behind the launch "involves enforcement discretion rather than FDA approval," and the peptides "have not been assessed by the FDA for safety and efficacy."

This desk checks claims against records. The claim moving through the coverage is that a regulatory door has opened and these compounds now stand on the other side of it. The door is real. What is on the other side of it is worth stating precisely.

What the company announced, in its own sequence

The launch did not start on Monday. On October 29, one day after the Department of Health and Human Services announced its draft peptide policy, the company previewed a Peptides+ specialty in its own release, naming sermorelin, glutathione, B12, NAD+, and L-carnitine as planned offerings, "with BPC-157 and TB-500 to follow when allowable." That release was a preview with a waitlist, not a product on sale. Monday's statement is the step from preview to launch: the first three products sell this month, and the two named peptides follow at a date the company has not fixed. Its chief financial officer told Reuters the revenue from the treatments is expected to be immaterial through the year, which is the company's own measure of how large this launch is at the start: a category being opened, not a business being transformed.

One detail in the company's ordering matters. Of the six compounds named in the federal draft, the two Hims & Hers plans to sell, BPC-157 and TB-500, are the ones with consumer demand behind them. The other four in the draft (epithalon, KPV, MOTS-c, and semax) appear nowhere in the company's announcement.

What the federal policy is, and what it is not

The policy is a draft enforcement discretion policy from the Department of Health and Human Services, published in the Federal Register on October 30 (91 FR 68526, docket HHS-OASH-2026-0496). In plain terms, it says the department does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding six named peptides for individual patients, provided a set of conditions is met, while the underlying compounding list goes through formal rulemaking. The six are BPC-157, TB-500, epithalon, KPV, MOTS-c, and semax, each limited to single-patient prescriptions.

The notice is explicit about its own limits. It is a draft. It does not establish rights for anyone and is not binding on the department or the public. And it approves nothing: compounded drugs are not FDA approved and are not reviewed by the FDA for safety, effectiveness, or quality, a sentence the federal documents state and the retail coverage mostly omits. Enforcement discretion means the government is choosing not to act against a practice it could act against. It is a decision about enforcement, not a finding about the compounds.

The reader's dated stake in this story is Friday. Public comments on the draft close at 11:59 p.m. Eastern on November 13, 2026, on docket HHS-OASH-2026-0496. After Friday, the draft sits with the department until a final version appears, on no published schedule.

What our library grades the named compounds

Glutathione, one of this month's three launches, grades C on evidence and D on worth it in our library, at $20 to $50 a month. The oral form's problem is absorption: the trial record for raising body glutathione levels on oral dosing is thin, and the grade reflects that.

BPC-157 grades D on evidence and D on worth it, at $30 to $60 a month. The record's basis is short enough to state in full: no published human randomized trial has tested the compound, human safety data does not exist, it is not approved for human use, and it is banned in sport by the World Anti-Doping Agency. TB-500 grades D on evidence and D on worth it, at $40 to $70 a month: no completed human trials of the fragment, documented purity problems in the products sold, an unresolved theoretical cancer concern, and the same sporting ban. These grades were set on October 17, before the federal draft existed. A change in enforcement posture is not new evidence, and neither grade moves on it.

Sermorelin, the third of this month's launches, is not graded in our library yet, and this piece does not grade it. It is in line to be graded, and it will be graded on its trial record when that record is built. NAD+ itself is sold here as a treatment; our library grades the oral precursors that raise it, NMN and NR, and the distinction between the molecule and its precursors is the subject of our NAD explainer.

How we grade Full records: BPC-157 and TB-500

Safety

Every compound named in this launch is a prescription-territory substance sold through a telehealth intake, and none has been assessed by the FDA for safety or efficacy, the regulator's own position as Reuters carried it. For the two peptides named as next, the safety record is an absence rather than a finding: BPC-157 has no human safety data at all, and TB-500 products carry documented purity problems, which means the contents of a given vial are part of the risk. Compounded products are not FDA reviewed for quality, so the manufacturing conditions the federal draft attaches (a registered manufacturer, one active ingredient per product, adverse-event reporting) are the protections that exist, and they are conditions of the enforcement posture, not approvals of any product.

Frequently asked questions

Has the FDA approved BPC-157 or TB-500? No. Neither compound has been assessed by the FDA for safety and efficacy. The federal draft is an enforcement discretion policy: the department states it does not intend to act against compounding that meets its conditions. That is not an approval, and the draft says so itself.

What can I do before Friday? The draft is open for public comment until 11:59 p.m. Eastern on November 13, 2026, on docket HHS-OASH-2026-0496. Comments from patients, clinicians, and compounders are the input the department reads before any final version.

Does the launch change your grades? No. Grades rest on human trial evidence, and a retail launch adds none. BPC-157 and TB-500 stood at D on evidence before the draft, and they stand there after it.

When will BPC-157 and TB-500 actually be on sale? The company has not fixed a date. Its own October wording was "when allowable," and its November statement says later. The CFO's guidance that revenue is immaterial through the year points the same way: not imminently.

Limitations: what we do not know

The company's November statement was reported by Reuters on November 9 and checked here against the company's October 29 release and the Federal Register notice; the launch's product pages, prices, and intake requirements were not public at the time of writing, so what a customer is actually offered, at what dose and price, is not yet checkable. Sermorelin's absence from our library is a gap this piece names rather than fills. And the federal draft may change between its comment close on Friday and any final version; this piece describes the draft as published on October 30.

Sources

  • Reuters, Niasse and Das, November 9, 2026: the launch announcement, the three November products, BPC-157 and TB-500 to follow with US manufacturing, the enforcement-discretion framing, and the CFO's revenue guidance.
  • Hims & Hers company release, October 29, 2026: the Peptides+ preview, the planned offerings, and "BPC-157 and TB-500 to follow when allowable."
  • Federal Register, 91 FR 68526, October 30, 2026: the draft enforcement discretion policy, docket HHS-OASH-2026-0496, comments closing November 13, 2026.
  • Longevity Lab Report records: BPC-157, TB-500, and glutathione (grades and costs as graded October 17, 2026).

Changelog

  • 2026-11-11: Published as the news desk's first piece under the newsroom directive. Verified against Reuters' November 9 report, the company's October 29 release, and the Federal Register notice before drafting.

Supplements mentioned

Peptides mentioned

Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.

Keep exploring

View all

The weekly newsletter

Keep up with what’s changing.

New research, useful tools, and the people shaping health and longevity. Selected and explained in one email.

See what you’ll receive ↗

Free. Confirm your email to subscribe. Unsubscribe anytime.